Vice versa, FLT3-wt patients were significantly more often affected by mutations in NRAS and KIT. No major difference between FLT3 mutant and -wt patients was observed for other frequently mutated genes in AML, such as IDH1 or TET2 (Table S2). This evidence concerns the gene KIT and acute myeloid leukemia.